Libre 3 Sensors: With Second Plant Online, Abbott Aims For Under-Penetrated ‘Intensive Insulin’ Segment

International sales could be a key driver as firm also looks to partnerships with insulin pump companies.

Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.

Despite previous supply challenges, Abbott said in its earnings call that it continues to report robust growth in the continuous glucose monitoring (CGM) market. (Shutterstock)
Key Takeaways
  • Abbott launched a new 323,000-square-foot manufacturing facility in Kilkenny, Ireland, employing more than 800 people to ramp up FreeStyle Libre 3 sensor production. 

      With the launch of its second manufacturing plant, Abbott is ramping up production of its FreeStyle Libre 3 sensors, aiming to expand its reach in the under-penetrated intensive insulin-using segment.

      Read the full article – start your free trial today!

      Join thousands of industry professionals who rely on Medtech Insight for daily insights

      • Start your 7-day free trial
      • Explore trusted news, analysis, and insights
      • Access comprehensive global coverage
      • Enjoy instant access – no credit card required

      More from Business

      More from Device Area